Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Not Applicable
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
- Interventions
- Other: Patient preference questionnaire
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT02551224
- Locations
- 🇦🇷
Novartis Investigative Site, Ciudad Autonoma de Bs As, Argentina
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT02550106
- Locations
- 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancy, France
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT02546674
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT02547714
- Locations
- 🇯🇵
Novartis Investigative Site, Shinjuku-Ku, Tokyo, Japan
Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos
Phase 1
Terminated
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02543086
- Locations
- 🇦🇺
Novartis Investigative Site, Brisbane, Queensland, Australia
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02534909
- Locations
- 🇱🇹
Novartis Investigative Site, Vilnius, Lithuania
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Phase 1
Completed
- Conditions
- cMET-dysregulated Advanced Solid Tumors
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT02520752
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta, Georgia, United States
A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
Phase 2
Completed
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02516605
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
Phase 4
Completed
- Conditions
- COPD
- Interventions
- Drug: Salmeterol/fluticasone 50/500 microgrammesDrug: QVA149 110/50 micrograms
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT02516592
- Locations
- 🇹🇷
Novartis Investigative Site, Yenisehir/Izmir, Turkey
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT02515331
- Locations
- 🇨🇭
Novartis Investigative Site, Lausanne, Switzerland
© Copyright 2025. All Rights Reserved by MedPath